Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 7Recruiting 6Active not recruiting 6Terminated 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

lanreotide 1famitinib 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated
19 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT01994213 2019-01-22

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
53 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡